

To: [redacted]@ec.europa.eu; [redacted]@bmg.bund.de; [redacted]@bmg.bund.de; [redacted]@aemps.es; [redacted]@aemps.es; [redacted]@bmg.bund.de; [redacted]@bmg.bund.de; [redacted]@sanita.it; [redacted]@sanita.it; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@igf.finances.gouv.fr; [redacted]@igf.finances.gouv.fr; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@pm.gouv.fr; [redacted]@pm.gouv.fr; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@bmg.bund.de; [redacted]@bmg.bund.de; [redacted]@pzh.gov.pl; [redacted]@pzh.gov.pl; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@gov.se; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu

Cc: [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu

From: [redacted]

Sent: Thur 1/14/2021 2:17:14 PM

Subject: RE: Proposal for additional supply of COVID-19 vaccine Moderna

Received: Thur 1/14/2021 2:17:14 PM

It would help a lot if we knew more about AZ, before we need to decide on this!

Verzonden met BlackBerry Work
(www.blackberry.com)

Van: [redacted]@ec.europa.eu

Datum: donderdag 14 jan. 2021 2:31 PM

Aan: [redacted]@bmg.bund.de; [redacted]@bmg.bund.de; [redacted]@aemps.es; [redacted]@aemps.es; [redacted]@bmg.bund.de; [redacted]@sanita.it; [redacted]@sanita.it; [redacted]@ec.europa.eu; [redacted]@igf.finances.gouv.fr; [redacted]@igf.finances.gouv.fr; [redacted]@ec.europa.eu; [redacted]@pm.gouv.fr; [redacted]@pm.gouv.fr; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@bmg.bund.de; [redacted]@bmg.bund.de; [redacted]@pzh.gov.pl; [redacted]@pzh.gov.pl; [redacted]@gov.se; [redacted]@minvws.nl; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu

Kopie: [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu; [redacted]@ec.europa.eu

Onderwerp: FW: Proposal for additional supply of COVID-19 vaccine Moderna

[To be discussed later in the meeting.](#)

From: [redacted]@modernatx.com

Sent: Thursday, January 14, 2021 1:55 AM

To: [redacted] (SANTE) <[redacted]@ec.europa.eu>

Cc: [redacted]@modernatx.com; [redacted]@modernatx.com; [redacted]@modernatx.com; [redacted]@modernatx.com

Subject: Proposal for additional supply of COVID-19 vaccine Moderna

Dear [redacted]

As discussed during our call on Tuesday, Moderna welcomes the opportunity to support you and the European Commission as you work diligently to secure additional supply of vaccines for citizens of the European members states. We share a common objective!

Please find attached a proposal for additional supply that we would appreciate discussing personally with you, in advance of your meeting with the EU Member States on Friday, January 15.

We will prioritize this personal call with you and would appreciate it if your assistant could kindly set up a call on Thursday at a convenient time.

Thanking you in advance.

Kind regards

 **Please consider the environment before printing this email**

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.